---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-291534"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2021-10-05T23:59:59+00:00"
generated_at: "2026-06-28T23:02:33.570524+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics appoints Samuel Allen Hamood to Board of Directors

## Summary
- Hamood elected as Class I director effective Oct 1, 2021; also chairs new Finance Committee.
- Annual cash retainers: $35,000 for Board, $5,000 for Finance Committee, $10,000 as chair.
- Initial equity grant: option to buy 25,543 shares at $12.94, $200,000 fair value, 3-year vest.
- Hamood serves as President and CAFO of Culligan International; 30+ years of finance experience.
- Board determined Hamood qualifies as independent under SEC and Nasdaq standards.

## SEC filing metadata
- accession: 0001193125-21-291534
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2021-10-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000119312521291534/0001193125-21-291534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000119312521291534/d222985d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-291534
- JSON: https://secwatch.observer/filing/0001193125-21-291534.json
- Plain text: https://secwatch.observer/filing/0001193125-21-291534.txt

## Key facts
- Executive change
  Samuel Allen Hamood was elected as Director at Finch Therapeutics Group, Inc..
  - Action: elected
  - Role: Director
  source text: elected Samuel Allen Hamood to the Board, effective immediately, to serve as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000119312521291534/0001193125-21-291534-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.